Dudziak R, Bonhard K
Anaesthesist. 1980 Apr;29(4):181-9.
The investigational concepts and experimental results of several research groups cooperating on haemoglobin solutions are reviewed over a ten years' period of time. Starting with solutions of stroma-cleared, nearly unaltered human erythrocyte haemoglobin they recognized the disadvantages of a high oxygen affinity, on one hand, and a short intravascular half-life on the other. The former drawback was first compensated by attempts to raise the 2,3-diphospho-glycerate level (Hb-DPG). Later on, better results were achieved by chemical modification of the free haemoglobin with pyrodixal-phospate. This type of pyridoxal-phosphate modified haemoglobin (HbPP) gained particular interest for myocardial perfusion. In order to prolong the intravascular efficiency of preparations to be infused into the central circulation, the pyridoxal-phosphate modified haemoglobin molecules were increased in size by intermolecular cross-linkage (HbHbPP). Possible clinical applications are argued of either type, HbPP and HbHbPP, respectively.
对几个合作研究血红蛋白溶液的研究小组在十年期间的研究概念和实验结果进行了综述。从去除基质、几乎未改变的人红细胞血红蛋白溶液开始，他们一方面认识到高氧亲和力的缺点，另一方面认识到血管内半衰期短的缺点。前一个缺点首先通过提高2,3-二磷酸甘油酸水平（Hb-DPG）的尝试得到补偿。后来，通过用磷酸吡哆醛对游离血红蛋白进行化学修饰取得了更好的结果。这种磷酸吡哆醛修饰的血红蛋白（HbPP）在心肌灌注方面引起了特别关注。为了延长注入体循环制剂的血管内效率，通过分子间交联增加了磷酸吡哆醛修饰的血红蛋白分子的大小（HbHbPP）。分别讨论了HbPP和HbHbPP这两种类型可能的临床应用。
